CDKN2A and neurofibroma: Based on a review of strong preclinical and clinical evidence, we propose the presence of CDKN2A/B biallelic inactivation as a sufficient molecular feature for the diagnosis of ANNUBP, even if the histopathology otherwise qualifies only for neurofibroma (Figure 1B).